Case Report: High TMB fails to predict immunotherapy response in PTCH1-mutant basal cell carcinoma with squamous differentiation
BackgroundTumor mutational burden (TMB) is widely utilized as a predictive biomarker for response to immune checkpoint inhibitors (ICIs). However, a subset of hypermutated tumors exhibits primary resistance to immunotherapy, indicating that additional …